Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/6/?d=1Neue Studien: Europe PMCdeLetter From the New Editor-in-Chief.https://www.psoriasis-news.de/articles.html/1_articles/letter-from-the-new-editor-in-chief-r526/No abstract supplied.

Weiterlesen

]]>526Thu, 12 Mar 2026 13:34:20 +0000The Impact of Tobacco Smoking on Treatment Response Among Patients With Psoriasis Undergoing Biologic Treatment: Prospective Observational Study.https://www.psoriasis-news.de/articles.html/1_articles/the-impact-of-tobacco-smoking-on-treatment-response-among-patients-with-psoriasis-undergoing-biologic-treatment-prospective-observational-study-r525/Weiterlesen

]]>525Thu, 12 Mar 2026 13:34:20 +0000Correction to "Successful Treatment With Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis".https://www.psoriasis-news.de/articles.html/1_articles/correction-to-successful-treatment-with-spesolimab-in-a-haemodialysis-patient-with-acutely-flaring-generalised-pustular-psoriasis-r524/Weiterlesen

]]>524Thu, 12 Mar 2026 13:34:20 +0000Establishing a Generalizable Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatmentshttps://www.psoriasis-news.de/articles.html/1_articles/establishing-a-generalizable-early-improvement-cutoff-in-psoriasis-area-and-severity-index-for-outcome-prediction-across-systemic-treatments-r523/Background Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real-world practice remains unclear. Objectives To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold applicable in routine clinical practice. Methods This prospective, multicenter real-world cohort study included adult patients with moderate-to-severe plaque psoriasis receiving methotrexate, phototherapy, IL-17 inhibitors, or IL-23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week-4 PASI improvement for achieving PASI90 at 3 months and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement. Results A total of 2,023 patients were included in the analysis. The optimal week-4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL-17 inhibitors, 62% for IL-23 inhibitors, 59% for methotrexate and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months. Conclusions Achieving PASI60 at week 4 serves as a consistent and broadly applicable early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. Incorporating this threshold into early treatment assessment may help inform individualized treatment decisions and optimize outcomes in real-world management of moderate-to-severe psoriasis.

Weiterlesen

]]>523Thu, 12 Mar 2026 13:34:20 +0000Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registry.https://www.psoriasis-news.de/articles.html/1_articles/determinants-of-quality-of-life-and-mental-health-in-kenyan-psoriasis-patients-a-cross-sectional-analysis-from-the-kenyan-psoriasis-registry-r522/Weiterlesen

]]>522Thu, 12 Mar 2026 13:34:20 +0000Α-Hederin alleviates psoriasiform skin inflammation by inhibiting NF-κB p65/CXCL2 Axis.https://www.psoriasis-news.de/articles.html/1_articles/%CE%B1-hederin-alleviates-psoriasiform-skin-inflammation-by-inhibiting-nf-%CE%BAb-p65cxcl2-axis-r521/BackgroundPsoriasis is a chronic, inflammatory and systemic skin disease. Currently, none of the treatment can effectively prevent the recurrent of psoriasis. α-Hederin is the main active ingredient of the traditional Chineses medicine Ivy, which has been proven to have anti-inflammatory effects. However, its effects on psoriasis and mechanisms of action remain unclear.

Objective

This study aimed to investigate the effects of α-Hederin on murine psoriasis and its underlying mechanisms.

Methods

This study firstly evaluated the therapeutic effects of α-Hederin on psoriasis using imiquimod-induced psoriatic mice. H&E and Ki67 immunohistochemical stainings were used to observe the pathological changes and proliferation of the skin lesions. The expression of inflammatory cytokines in skin lesions was analyzed by ELISA. Subsequently, the network pharmacology was employed to predict the molecular targets of α-Hederin in psoriasis. CXCL2 expression and neutrophil infiltration in skin lesions were evaluated via immunohistochemical staining, immunofluorescent staining and flow cytometry. Finally, the effects of α-Hederin on NF-κB p65 pathway were evaluated. The binding of α-Hederin to NF-κB p65 protein was verified through molecular docking, molecular dynamics simulation, CETSA and DARTS.

Results

α-Hederin significantly improved IMQ-induced psoriasiform skin lesions and inflammation in mice. It also reduced the expression of CXCL2 and infiltration of CD11b+Ly6G+ neutrophils in the skin of psoriatic mice. Importantly, administration of recombinant CXCL2 protein aggravated the skin lesions and increased CD11b+Ly6G+ neutrophil infiltration in psoriatic mice previously treated with α-Hederin. Furthermore, α-Hederin inhibited the production of CXCL2 in HaCaT cells and migration of neutrophils to HaCaT cells. But these effects were completely reversed by the CU-T12-9, an NF-κB p65 agonist. Similarly, α-Hederin failed to further alleviate psoriasiform skin lesions and inflammation in mice treated with SC75741 (NF-κB p65 inhibitor). Finally, based on molecular docking, molecular dynamics simulation, CETSA and DARTS, NF-κB p65 was revealed as the direct target of α-Hederin in treating psoriasis.

Conclusion

This study has provided the first evidence that α-Hederin may be a promising anti-psoriatic drug by inhibiting NF-κB p65/CXCL2 axis.

Weiterlesen

]]>521Wed, 11 Mar 2026 16:16:46 +0000Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.https://www.psoriasis-news.de/articles.html/1_articles/nanocarriers-smart-biomaterials-and-emerging-therapeutics-for-psoriasis-current-progress-and-future-directions-r520/Weiterlesen

]]>520Wed, 11 Mar 2026 16:16:46 +0000Correction to “Successful Treatment With Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis”https://www.psoriasis-news.de/articles.html/1_articles/correction-to-successful-treatment-with-spesolimab-in-a-haemodialysis-patient-with-acutely-flaring-generalised-pustular-psoriasis-r519/No abstract supplied.

Weiterlesen

]]>519Wed, 11 Mar 2026 16:16:46 +0000Screening practice of cardiovascular risk and psoriatic arthritis among patients with psoriasis in primary care.https://www.psoriasis-news.de/articles.html/1_articles/screening-practice-of-cardiovascular-risk-and-psoriatic-arthritis-among-patients-with-psoriasis-in-primary-care-r518/BackgroundGeneral Practitioners (GPs) act as primary gatekeepers for patients with psoriasis and their screening practice for cardiovascular disease (CVD) and psoriastic arhtiris (PsA) y. This study aimed to assess the awareness and screening routines of Danish GPs regarding CVD and PsA in patients with psoriasis.

Methods

A nationwide cross-sectional survey on screening practice was conducted involving 490 randomly selected Danish GPs. Data were analyzed descriptively based on 101 responses (21% response rate).

Results

The survey revealed a high level of awareness regarding CVD risk (84%), with 60% of GPs reporting routine screening for cardiovascular issues. Commonly assessed parameters included blood pressure (93%) and cholesterol (67%). Conversely, screening for PsA was notably less frequent, with only 32% of GPs actively screening for PsA.

Conclusion

While screening and awareness of CVD risk among primary care professionals, PsA screening remains suboptimal. The findings suggest an urgent need for updated guidelines endorsing simple, validated PsA screening tools and targeted education to prevent missed opportunities for early diagnosis.

Weiterlesen

]]>518Wed, 11 Mar 2026 15:51:58 +0000Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events.https://www.psoriasis-news.de/articles.html/1_articles/choice-of-biologic-immunotherapy-for-psoriasis-or-psoriatic-arthritis-and-its-association-with-risk-of-major-adverse-cardiac-events-r517/ObjectiveIndividuals with psoriasis (PsO) or psoriatic arthritis (PsA) have an elevated risk of major adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardial infarction (MI), and cerebrovascular accident (CVA). Biologic disease-modifying antirheumatic drugs (bDMARDs) may reduce cardiovascular risk; however, whether MACE risk differs by bDMARD class for this population is unknown.

Methods

Using data from TriNetX database, we identified patients with PsO/PsA who were new bDMARD users, including tumor necrosis factor inhibitors (TNFi), interleukin (IL)-17A inhibitors (-i), IL-23i, or IL-12/23i. Time-dependent risk for MACE was calculated using weighted multinomial Cox proportional hazards regression with TNFi exposure as the referent. Additional analyses evaluated components of the primary outcome and baseline cardiovascular disease. A negative control outcome was used to assess bias.

Results

We identified 32,758 patients with PsO/PsA who were new bDMARD users. Patients had PsO/PsA for a mean of 3.5 (SD 4.5) years prior to starting a biologic, the most common being TNFi (62.9%), followed by IL-17i (15.4%), IL-23i (11%), and IL-12/23i (10.7%). In weighted multinomial Cox proportional hazards regression, the adjusted risk of MACE was similar for IL-17Ai (adjusted hazard ratio [aHR] 0.98, 95% CI 0.73-1.32), IL-23i (aHR 0.84, 95% CI 0.54-1.31), and IL-12/23i (aHR 1.08, 95% CI 0.80-1.47) as compared to TNFi. Subset analyses supported the primary analysis. Negative control outcomes suggested adequate control of bias confounding.

Conclusion

MACE risk does not significantly differ across bDMARD classes in patients with PsO/PsA. Therefore, cardiovascular risk should not guide biologic selection in this population.

Weiterlesen

]]>517Wed, 11 Mar 2026 15:51:58 +0000Clinical characteristics, effectiveness, safety, and predictors of PASI75/90 responses to IL-17 biologics in psoriasis involving special sites: a large real-world cohort study revealing treatment response heterogeneity.https://www.psoriasis-news.de/articles.html/1_articles/clinical-characteristics-effectiveness-safety-and-predictors-of-pasi7590-responses-to-il-17-biologics-in-psoriasis-involving-special-sites-a-large-real-world-cohort-study-revealing-treatment-response-heterogeneity-r516/P < 0.0001. Treatment response rates were 74.0% for PASI50, 58.6% for PASI75, and 41.5% for PASI90, while adverse events were rare (0.75%). Prediction models for PASI75 and PASI90 responses exhibited moderate discriminative ability. Independent predictors for both PASI75 and PASI90 included clinical BMI, DLQI, BSA, and IGA (all P < 0.05), while job status was an independent predictor for PASI90 only (P < 0.05).Overall, IL-17 inhibitors show substantial efficacy and a favorable safety profile for psoriasis in special sites, with treatment response variability influenced primarily by baseline clinical characteristics such as BMI and disease severity indices.

Weiterlesen

]]>516Wed, 11 Mar 2026 15:51:58 +0000Integrating network pharmacology and experimental validation to elucidate the mechanism of Xiao-bi decoction in psoriasis treatment: Inhibition of JAK2/STAT3 signaling and rebalancing Th17/Treg responses.https://www.psoriasis-news.de/articles.html/1_articles/integrating-network-pharmacology-and-experimental-validation-to-elucidate-the-mechanism-of-xiao-bi-decoction-in-psoriasis-treatment-inhibition-of-jak2stat3-signaling-and-rebalancing-th17treg-responses-r515/Ethnopharmacological relevanceThe traditional Chinese herbal medicine called Xiao-bi decoction (XBD) has been used for decades to treat psoriasis, but its mechanism of action is poorly understood.

Aim of the study

To investigate the underlying mechanism of XBD against psoriasis using systematic pharmacological techniques.

Materials and methods

A psoriasis model was established in mice using imiquimod (IMQ). The efficacy of XBD was evaluated based on psoriasis severity scores and immune cell infiltration. Core components and targets were screened using UPLC-QE-MS/MS and network pharmacology. The mechanism was further explored via transcriptome sequencing, ELISA, western blotting, immunolocalization, and molecular docking.

Results

XBD treatment significantly alleviated IMQ-induced psoriatic symptoms like erythema, scaling, and thickening. It reduced CD4+ T cell infiltration in skin and decreased serum levels of IL-17, IL-1β, IL-23, and IL-36. XBD specifically decreased CD4+-IL-17+ cells while increasing CD4+-FoxP3+ cells in both blood and skin. A total of 1223 chemical components were identified in XBD, including 78 blood-entering components. Network pharmacology and transcriptome analysis collectively demonstrate that XBD inhibits the activation of the JAK2/STAT3 signaling pathway, indicating its potential role in modulating this pathway. Our results also showed that XBD modulated Th17/Treg balance in serum and ameliorating skin inflammation in IMQ-induced psoriatic model.

Conclusion

The herbal medicine Xiao-bi decoction may regulate the JAK2/STAT3 pathway, thereby influencing the Th17 response and Treg differentiation, and thereby alleviating the skin inflammation of psoriasis.

Weiterlesen

]]>515Wed, 11 Mar 2026 15:51:58 +0000Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/baseline-clinical-and-metabolic-predictors-of-52-week-durability-of-secukinumab-response-in-moderate-to-severe-plaque-psoriasis-r514/BackgroundDurability of response to IL-17A blockade (secukinumab) varies, representing a major clinical challenge. Psoriasis is inherently linked to immunometabolic dysfunction. We hypothesized that simple, routine metabolic indices could predict long-term treatment stability, offering crucial pre-treatment stratification tools.

Methods

This was a 52-week prospective, single-center cohort study of 118 patients with moderate-to-severe plaque psoriasis initiating secukinumab. We defined Durable Response (DR) as PASI90 at Week 12 maintained as absolute PASI ≤ 2 until Week 52. Multivariable logistic regression and Cox models were used to identify independent predictors of DR and drug survival.

Results

Independent predictors of durable response were biologic-naïve status (adjusted OR = 3.52, 95% CI: 1.58-7.85) and a lower baseline TG/HDL-C ratio (adjusted OR = 0.61, 95% CI: 0.47-0.79). Conversely, obesity (BMI≥30) (OR = 0.42) and higher baseline PASI (OR = 0.91) were associated with reduced odds of DR. Conventional systemic inflammatory markers (CRP, NLR) showed no significant difference. Drug survival was significantly higher in DRs (92.6% vs 78.3% at Week 52) and was independently reduced by psoriatic arthritis.

Conclusion

The routine baseline TG/HDL-C ratio is a strong, independent predictor of sustained secukinumab efficacy. These easily accessible clinical and metabolic features capture the immunometabolic milieu influencing IL-17A inhibition durability. Integrating the TG/HDL-C ratio into pre-treatment assessment can support patient stratification and optimize long-term management strategies for plaque psoriasis.

Weiterlesen

]]>514Wed, 11 Mar 2026 15:51:58 +0000The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review.https://www.psoriasis-news.de/articles.html/1_articles/the-emerging-role-of-gut-microbiota-in-inflammatory-skin-diseases-a-systematic-review-r513/Weiterlesen

]]>513Wed, 11 Mar 2026 15:51:58 +0000PBMC transcriptomic signatures reflect immune dynamics and disease activity in psoriatic arthritishttps://www.psoriasis-news.de/articles.html/1_articles/pbmc-transcriptomic-signatures-reflect-immune-dynamics-and-disease-activity-in-psoriatic-arthritis-r512/No abstract supplied.

Weiterlesen

]]>512Wed, 11 Mar 2026 15:51:58 +0000Letter From the New Editor-in-Chiefhttps://www.psoriasis-news.de/articles.html/1_articles/letter-from-the-new-editor-in-chief-r511/No abstract supplied.

Weiterlesen

]]>511Wed, 11 Mar 2026 15:51:58 +0000Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registryhttps://www.psoriasis-news.de/articles.html/1_articles/determinants-of-quality-of-life-and-mental-health-in-kenyan-psoriasis-patients-a-cross-sectional-analysis-from-the-kenyan-psoriasis-registry-r510/No abstract supplied.

Weiterlesen

]]>510Wed, 11 Mar 2026 15:51:58 +0000Real-World Effectiveness and Safety of Tapinarof 1% Cream in Psoriasis: An Observational Study From Bangladeshhttps://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-and-safety-of-tapinarof-1-cream-in-psoriasis-an-observational-study-from-bangladesh-r509/No abstract supplied.

Weiterlesen

]]>509Wed, 11 Mar 2026 15:51:58 +0000Bone properties and biomechanics in patients with psoriatic disease: a cross-sectional study with high-resolution peripheral quantitative CT (HRpQCT).https://www.psoriasis-news.de/articles.html/1_articles/bone-properties-and-biomechanics-in-patients-with-psoriatic-disease-a-cross-sectional-study-with-high-resolution-peripheral-quantitative-ct-hrpqct-r505/BackgroundPsoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular compartments remain poorly understood. The aim of this study was to investigate the prevalence and determinants of bone microarchitectural damage in patients with psoriatic disease.

Methods

We performed a cross-sectional study in patients with psoriasis (PsO), psoriatic arthritis (PsA) and age-matched healthy controls (HCs) recruited into the Department of Dermatology and Rheumatology of Verona centre. We conducted high-resolution peripheral quantitative CT of the radius and finger joints of the non-dominant hand. Bone microstructure parameters and finite element analysis (uFEA) were calculated.

Results

51 patients with PsO and 39 patients with PsA were consecutively enrolled in the study. 24 age-matched HCs were enrolled. Distal radius total and cortical volumetric bone mineral density (Ct.BMD) levels were lower in patients with PsA and PsO compared with HC. On distal radius uFEA analysis, we found a significant reduction of stiffness in PsA compared with both HC and PsO. At the distal interphalangeal (DIP) joints, Ct.BMD and trabecular volumetric bone mineral density were lower in PsA and PsO compared with HC. Nail involvement in psoriatic disease was negatively associated with bone stiffness at the proximal and distal region of the DIPs.

Conclusion

Psoriatic disease negatively impacted bone integrity. Patients with psoriatic disease seemed to have lower bone density and more microarchitectural alteration that impacted on biomechanics properties. Nail involvement was associated with decreased bone stiffness in psoriatic disease.

Weiterlesen

]]>505Wed, 11 Mar 2026 05:52:24 +0000Isolinderalactone targets TNF-α/STAT3 inflammatory pathways to attenuate psoriasis-like dermatitis.https://www.psoriasis-news.de/articles.html/1_articles/isolinderalactone-targets-tnf-%CE%B1stat3-inflammatory-pathways-to-attenuate-psoriasis-like-dermatitis-r504/BackgroundGiven the proinflammatory cascade elicited by tumor necrosis factor-α (TNF-α) in psoriasis, multiple TNF-α-targeted biologics have been developed for psoriasis treatment. Although systemic macromolecular biologics are widely used, a crucial therapeutic gap remains for mild-to-moderate psoriasis, underscoring an unmet need for more effective topical drugs suppressing TNF-induced inflammatory signaling.

Objective

To identify a novel potent natural small-molecule drug suppressing TNF-induced inflammatory signaling and elucidate its therapeutic mechanism in psoriasis.

Methods

First, candidate small-molecule drugs were screened out through a high-throughput screening platform. Next, the therapeutic effect of Isolinderalactone was evaluated through topical application in the imiquimod (IMQ)-induced psoriasis-like mouse model. Subsequently, RNA sequencing (RNA-seq) analysis of TNF-α-stimulated HaCaT cells and epidermis of IMQ-treated mice identified key transcriptomic alterations induced by Isolinderalactone treatment. Finally, anti-psoriasis effects and underlying mechanisms of Isolinderalactone were verified in both in vivo and in vitro experiments.

Results

Isolinderalactone was identified as a potent drug suppressing TNF-related signaling with low cytotoxicity. Topical application of Isolinderalactone significantly alleviated IMQ-induced psoriasis-like dermatitis. Conjoint analysis of RNA-seq for TNF-α-stimulated HaCaT cells and epidermis from lesions of IMQ-treated mice revealed Isolinderalactone downregulated the expression of TNF-α, interleukin-17 (IL-17) and S100-related inflammatory factors in epidermal keratinocytes. Mechanistically, Isolinderalactone significantly inhibited the TNF-α/STAT3 inflammatory pathways in epidermal keratinocytes and exerted an anti-inflammatory effect.

Conclusion

Isolinderalactone exhibits anti-inflammatory activity through multiple mechanisms, highlighting the potential of topical Isolinderalactone therapy for mild-to-moderate psoriasis.

Weiterlesen

]]>504Wed, 11 Mar 2026 05:52:24 +0000Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/validation-of-performance-of-spanish-version-of-pure-4-questionnaire-for-early-identification-of-psoriatic-arthritis-after-1-year-of-follow-up-in-patients-with-psoriasis-r503/Background and objectivePsoriatic arthritis (PsA) is an inflammatory, chronic and progressive musculoskeletal disease associated with psoriasis. The validation of the Spanish version of the Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) questionnaire has been published previously. The present analysis studied the performance of the PURE-4 questionnaire for the early detection of PsA one year before its diagnosis.

Materials and methods

This was an observational multicenter study, including two cross-sectional assessments, with primary data collection in routine clinical practice in Spain. Adult patients with psoriasis and confirmed not having PsA diagnosis during Assessment I completed Assessment II by the rheumatologist one year (±2 months) after answering the PURE-4 questionnaire. This work presents the results of Assessment II, to confirm/rule out the presence of PsA in patients with psoriasis one year after PURE-4 answering. The analysis, involving the results from Assessment II, will evaluate the performance of the PURE-4 questionnaire for the early detection of potential PsA in terms of sensitivity and specificity.

Results

There were 219 evaluable patients, 56.2% male, and the mean (standard deviation [SD]) age was 46.8 (12.5) years. At one year, the PsA diagnosis was confirmed in 12 (5.5%) patients, representing 26.1% of the total number of patients with PsA diagnosed since the beginning of the study. The mean (SD) PURE-4 score was 2.4 (1.1) for patients with PsA and 1.2 (1.2) for patients without a diagnosis of PsA (p = 0.0016). The area under the receiver-operating characteristic (ROC) curve confirmed the good quality of the questionnaire (0.7618; 95% CI: 0.6530-0.8706; n = 217). PURE-4 showed a sensitivity of 75.0% and a specificity of 62.9%.

Conclusions

The PURE-4 questionnaire offers good clinimetric capabilities for the early detection of PsA with a score ≥2. Of the total number of patients with PsA, one in four were detected one year after answering positively to the questionnaire, which would help to predict which patients are at high risk of developing PsA. The authors reinforce the recommendation to closely follow up with these patients.

Weiterlesen

]]>503Wed, 11 Mar 2026 05:52:24 +0000Association Between Inflammatory Cytokines and Systemic Inflammation Indices in Patients With Psoriasis: A Cross-Sectional Study.https://www.psoriasis-news.de/articles.html/1_articles/association-between-inflammatory-cytokines-and-systemic-inflammation-indices-in-patients-with-psoriasis-a-cross-sectional-study-r502/Background and objectivesSystemic inflammation indices derived from complete blood counts (CBC) are accessible markers of inflammatory burden, but their relationship with circulating cytokines in psoriasis remains unclear. We investigated associations between CBC-derived indices and serum cytokines in psoriasis.

Materials and methods

In this cross-sectional study, we included 28 patients with psoriasis and 23 healthy controls. Serum IL-17, IL-22, IL-23, IL-31, IL-33, IL-36, TNF-α, TGF-β, and IFNγ were quantified by ELISA. CBC-derived indices were computed (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV). Case-control comparisons used the full sample. Cytokine-index associations were evaluated in psoriasis patients using bivariate correlations and multivariate GLM adjusted for age, smoking, and NAFLD. Multiplicity was controlled using Benjamini-Hochberg false discovery rate (BH-FDR); prespecified sensitivity analyses used log-transformed cytokines and Spearman correlations.

Results

Psoriasis patients had higher levels of all cytokines (all p < 0.001) and higher SIRI versus controls (p < 0.001; q = 0.005). PIV showed a nominal case-control difference (p = 0.022) that did not remain significant after BH-FDR (q = 0.055), while NLR, PLR, and SII did not differ. In adjusted multivariate GLM, TGF-β showed a global association with the joint set of indices (Pillai's trace = 0.295; p = 0.039) that did not survive BH-FDR (q = 0.507) and was attenuated with log-transformation. Nominal univariate effects for TNF-α on SIRI (F = 4.600; p = 0.039) and PIV (F = 5.660; p = 0.023) did not remain significant after BH-FDR.

Conclusions

SIRI was consistently elevated in psoriasis, whereas PIV showed a nominal difference versus controls. Across exploratory analyses, SIRI and PIV showed the most consistent directional co-variation with cytokines, but associations were modest. These findings are hypothesis-generating and support further validation in larger cohorts to determine whether CBC-derived indices can serve as scalable adjunct markers of inflammatory activity in psoriasis.

Weiterlesen

]]>502Wed, 11 Mar 2026 05:52:24 +0000Transcriptomic Analysis of Differentially Expressed Lipid Metabolism-Related Genes in Psoriasis Patientshttps://www.psoriasis-news.de/articles.html/1_articles/transcriptomic-analysis-of-differentially-expressed-lipid-metabolism-related-genes-in-psoriasis-patients-r501/Psoriasis, a chronic and recurring disease, is closely associated with lipid metabolism. This study aims to identify differentially expressed genes (DEGs) and their functional pathways associated with psoriasis to uncover new therapeutic targets. We leveraged Gene Expression Omnibus (GEO) datasets for DEGs analysis in psoriasis. Gene Set Enrichment Analysis (GSEA), Gene Set Variation Analysis (GSVA), Weighted Gene Co-expression Network Analysis (WGCNA), and single-sample GSEA (ssGSEA) were used to investigate the roles of lipid metabolism genes in psoriasis progression and immune alterations. An RBP-mRNA network revealed post-transcriptional regulatory mechanisms. Our findings revealed 3,839 DEGs, including 1,775 upregulated and 2,064 downregulated genes in psoriatic samples compared to controls. Enrichment analysis showed that immune-related pathways such as cytoplasmic DNA sensing pathways and NOD-like receptor signaling pathways were significantly enriched. WGCNA identified modules highly correlated with lipid metabolism and screened out key genes such as AACS, HSD11B1 and GATA6. ROC curve analysis showed that these genes had a high discriminatory ability (AUC > 0.85) within the analyzed dataset, suggesting their potential as novel biomarkers. Immune infiltration analysis revealed significant differences in 27 types of immune cells between patients with psoriasis and the control group. This study provides new clues for the molecular mechanism of psoriasis and potential therapeutic targets.

Weiterlesen

]]>501Wed, 11 Mar 2026 05:52:24 +0000Correction: Ketogenic diet improves disease activity and cardiovascular risk in psoriatic arthritis: A proof of concept study.https://www.psoriasis-news.de/articles.html/1_articles/correction-ketogenic-diet-improves-disease-activity-and-cardiovascular-risk-in-psoriatic-arthritis-a-proof-of-concept-study-r500/Weiterlesen

]]>500Wed, 11 Mar 2026 05:52:24 +0000Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.https://www.psoriasis-news.de/articles.html/1_articles/real-world-burden-of-generalized-pustular-psoriasis-in-a-french-observational-study-prevalence-incidence-healthcare-resource-utilization-comorbidities-treatment-use-and-mortality-r499/IntroductionGeneralized pustular psoriasis (GPP) is rare, chronic, and associated with life-threatening complications. We investigated the burden of GPP in France.

Methods

Using data from 2010 to 2021 in the Système National des Données de Santé database, healthcare resource utilization (HCRU), costs, comorbidities, mortality, and treatments were compared among GPP (N = 4351), plaque psoriasis (N = 12,945), and general population (N = 12,981) cohorts, matched for sex, age, Charlson Comorbidity Index (CCI) score, and region. GPP prevalence and incidence were also investigated.

Results

Annually, there were 0.5-0.8 new GPP cases per 100,000 people. Across the cohorts, 54.5-54.7% of people were male, with mean age 58.7-59.5 years and mean CCI score 1.98-2.06. The GPP cohort incurred significantly greater HCRU and costs versus the plaque psoriasis and general population cohorts, including greater proportions of patients receiving emergency care (78% vs 63% and 55%) and intensive care (28% vs 17% and 14%), longer hospitalizations (mean 38.5 vs 26.2 and 22.4 days per patient), and higher medication costs (€4360 vs €1991 and €1543 per patient-year), respectively. Despite similar CCI scores, GPP was associated with more cardiometabolic and psychological comorbidities versus the plaque psoriasis and general population cohorts, e.g., hypertension (37% vs 21% and 20%), obesity (21% vs 9% and 6%), depression (13% vs 4% and 4%), alcohol abuse (16% vs 3% and 3%), and sleep disorders (8% vs 4% and 3%), respectively. Treatments in the GPP cohort were those used for plaque psoriasis, including topical steroids (77%), systemic steroids (50%), and biologics (23%). Twelve-month survival was 86.9% (GPP), 97.5% (plaque psoriasis), and 90.0% (the general population).

Conclusion

HCRU, costs, and comorbidities with GPP were often double those for comparator cohorts, and mortality was higher. These findings highlight the need to use GPP-targeted treatments that improve patient outcomes and may reduce the burden on healthcare systems.

Weiterlesen

]]>499Wed, 11 Mar 2026 05:52:24 +0000